Printer Friendly

ISIS RECEIVES FDA APPROVAL TO BEGIN CLINICAL TRIALS ON ANTISENSE HPV DRUG

 ISIS RECEIVES FDA APPROVAL TO BEGIN CLINICAL TRIALS
 ON ANTISENSE HPV DRUG
 CARLSBAD, Calif., March 4 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIP), today announced that it has received approval from the Food and Drug Administration (FDA) to initiate clinical trials on a new drug (ISIS 2105) to treat human papillomavirus. Isis filed an investigational new drug (IND) application on Jan. 29, 1992. The company plans to initiate Phase I clinical trials immediately, which will make ISIS 2105 the first antisense drug to be administered to humans.
 "The approval of the IND for ISIS 2105 represents an important milestone for the company," said Stanley T. Crooke, M.D., Ph.D., chairman and chief executive officer. "We are particularly pleased with the careful, attentive review that the IND received at the FDA," said Daniel Kisner, M.D., executive vice president.
 ISIS 2105 is an antisense compound designed to inhibit the growth of papilloma viruses, the viruses that cause genital warts. "Preclinical data on ISIS 2105 suggest that it may be able to cure genital warts and rid the patient of the virus. We are excited by the opportunity to test this compound in humans," said Christopher Mirabelli, Ph.D., senior vice president for research and preclinical development.
 Antisense drugs bind to messenger RNA molecules that code for disease-causing proteins, thereby inhibiting their production. In contrast, a traditional drug inhibits the performance of a single disease-causing protein after its synthesis. As a result, the therapeutic benefit of antisense drugs at this stage in the disease- causing process has the potential to be more pronounced than that of traditional drugs.
 The incidence of genital warts is growing rapidly. In 1989, nearly 1.5 million office visits for genital warts were recorded in the United States. HPV infections of the cervix are associated with cervical cancer in infected women and with laryngeal papillomatosis in the newborns of infected mothers. Current treatment for HPV infections are not curative and recurrences are frequent. Surgical interventions, the most common treatment, may cause spreading of the virus and are painful, disfiguring and often unsuccessful.
 Initial clinical trials of ISIS 2105 will employ intralesional injections to treat HPV.
 Isis Pharmaceuticals, Inc., based in northern San Diego County, is engaged in the discovery, development and marketing of novel drugs based on antisense oligonucleotides.
 -0- 3/4/92
 /CONTACT: Daniel L. Kisner, M.D., executive vice president of Isis Pharmaceuticals, 619-931-9200; or Anthony J. Russo of Noonan/Russo Communications, 212-979-9180, for Isis Pharmaceuticals/
 (ISIP) CO: Isis Pharmaceuticals, Inc. ST: California IN: MTC SU:


GK-TS -- NY017 -- 4832 03/04/92 09:33 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 4, 1992
Words:430
Previous Article:GE CAPITAL COMPUTER LEASING NAMES CLEMENTS SENIOR VICE PRESIDENT OF PORTFOLIO MARKETING AND MANAGEMENT
Next Article:SNO COUNTRY REPORTS OFFICIAL SKI REPORT FOR MARCH 24, 1992
Topics:


Related Articles
Isis Receives $10 Million Milestone Payment from Boehringer Ingelheim for Isis 2302
Isis Shows Second Generation Chemistry Increases Potency And Validates Novel Antisense Mechanism of Action
Isis Pharmaceuticals enters into agreement with Pfizer.
Antisense Therapeutics Limited and Isis Pharmaceuticals Initiate Phase I Trial of Antisense Drug for Multiple Sclerosis.
Hybridon Receives Patent Sublicense Income From Isis Pharmaceuticals.
OncoGenex Technologies and Isis Pharmaceuticals Achieve Alliance Milestone: Initiate Phase I Clinical Trial of Antisense Drug in Prostate Cancer.
Isis Pharmaceuticals and Elan Corporation Conclude Collaboration In HepaSense Joint Venture and Restructure OraSense Collaboration.
OncoGenex Initiates First of Four Phase 2 Clinical Trials of OGX-011 in Cancer.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters